

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
28 April 2005 (28.04.2005)


PCT

(10) International Publication Number
WO 2005/037261 A1

- (51) International Patent Classification⁷: **A61K 31/00**, 39/00, 39/395
- (21) International Application Number: **PCT/US2004/033988**
- (22) International Filing Date: 14 October 2004 (14.10.2004)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:
60/510,516 14 October 2003 (14.10.2003) US
60/576,624 4 June 2004 (04.06.2004) US
- (71) Applicant (for all designated States except US): **BIOMIRA, INC.** [CA/CA]; Edmonton Research Park, 2011 - 94 Street, Edmonton, 1 TGN 1H1 (CA).
- (72) Inventors; and
- (75) Inventors/Applicants (for US only): **KEHOE-WHISTANCE, Mairread** [CA/US]; 104 East Becks Road, Ringoes, NJ 08551 (US). **MACLEAN, Grant** [CA/CA]; 6476 Oldfield Road, Victoria, British Columbia V8M 1X8 (CA).
- (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
- (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

[Continued on next page]

(54) Title: COMBINATION THERAPY FOR CANCER



(57) Abstract: Anti-hormonal (anti-estrogenic steroid) therapy and immunotherapy are used in combination to treat breast cancer. The preferred immunotherapeutic agent is an immunogen, preferably comprising sialyl-Tn, and more preferably is a sialyl-Tn/KLH conjugate.



Published:

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.